Isik Ahmet Turan, Soysal Pinar, Yay Adnan
Department of Geriatric Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey
Department of Geriatric Medicine, School of Medicine, Dokuz Eylul University, Izmir, Turkey.
Am J Alzheimers Dis Other Demen. 2014 Dec;29(8):735-8. doi: 10.1177/1533317514536598. Epub 2014 May 26.
Rivastigmine is commonly used for the treatment of Alzheimer's disease (AD). All cholinesterase inhibitors, including rivastigmine, may cause cardiac side effects. The aim of this study is to compare the electrocardiographic (ECG) and hypotensive effects of formulations of rivastigmine.
Eighty-five newly diagnosed patients with AD who were treated with rivastigmine were retrospectively evaluated. The ECG records were reviewed at baseline and at administration of either 12 mg of oral rivastigmine or 10 cm(2) transdermal rivastigmine.
When compared with the baseline, there were no changes in any of the ECG parameters in all of the patients (P > .05). Moreover, when compared with the mean change from baseline for each treatment group, there were no changes, except heart rate (P = .035).
It was demonstrated that rivastigmine formulations were not associated with increased arrhythmogenic or hypotensive effects in elderly patients with AD and was not superior to each other.
利伐斯的明常用于治疗阿尔茨海默病（AD）。所有胆碱酯酶抑制剂，包括利伐斯的明，都可能引起心脏副作用。本研究的目的是比较利伐斯的明不同剂型的心电图（ECG）和降压效果。
对85例新诊断的接受利伐斯的明治疗的AD患者进行回顾性评估。在基线时以及给予12 mg口服利伐斯的明或10 cm²透皮利伐斯的明时对心电图记录进行复查。
与基线相比，所有患者的任何心电图参数均无变化（P > 0.05）。此外，与每个治疗组基线时的平均变化相比，除心率外（P = 0.035）均无变化。
结果表明，利伐斯的明剂型在老年AD患者中与心律失常或降压作用增加无关，且各剂型之间无优劣之分。
